SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

GTBP

GT Biopharma, Inc.
NASDAQHealth Care

Latest close: 7.03 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record◆Adverse 8-K filing●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 25, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 21, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Sep 15, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record78213 flagged findings
Reported transactions (Form 4)19since Jan 27, 2023
Corporate events (8-K)30since Feb 28, 2023

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-09-15share offering or dilution eventfreshOpen filing ↗
    “…exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise equal to five years.…”
  • 2026-09-03share offering or dilution eventfreshOpen filing ↗
    “…the Reverse Stock Split is 36254L 407. As a result of the Reverse Stock Split, the issued and outstanding shares of Common…”
    +1 more passage from the same document
    • “…The Reverse Stock Split will apply to the Company’s outstanding convertible securities, warrants, stock options and restricted…”
  • 2026-09-03reverse splitfreshOpen filing ↗
    “…herein by reference. Certificate of Amendment - Reverse Stock Split and Reduction in Authorized Shares In addition to…”
    +1 more passage from the same document
    • “…filing the Certificates of Elimination, on September 2, 2026, the Company also filed a Certificate of Amendment (the “Certificate of…”
  • 2026-08-14reverse splitfreshOpen filing ↗
    “…423,433 246,384 — 3. The proposal to approve, on a non-binding advisory basis, the Company’s executive compensation was approved…”
    +1 more passage from the same document
    • “…6,057,507 2,162,518 310,220 14,827,479 4. The proposal to approve an amendment to the Company’s restated certificate of…”
  • 2026-08-14share offering or dilution eventfreshOpen filing ↗
    “…with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that Z-One, LLC…”
    +1 more passage from the same document
    • “…with Notice in the Supreme Court of the State of New York, County of New York. The Company then filed a demand that Z-One, LLC…”
  • 2026-08-14listing compliance noticefreshOpen filing ↗
    “…31, 2026. Contingency – NASDAQ Matters On November 20, 2025, the Company received a letter (the “2025 Letter”) from the Nasdaq…”
    +1 more passage from the same document
    • “…Qualifications Staff (the “Staff”) notifying the Company that its Common Stock had closed below $1.00 per share for 30 consecutive…”
  • 2026-08-14reverse splitfreshOpen filing ↗
    “…19, 2026 (the “Compliance Period”), to regain compliance with the Minimum Bid Price requirement. On May 12, 2026, the Company…”
  • 2026-03-06share offering or dilution eventrecentOpen filing ↗
    “…June 30, 2025 4,995,263 $ 5.49 The aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as…”
    +1 more passage from the same document
    • “…limitations, immediately upon issuance and have a term of exercise equal to five years . An aggregate of 11,576,406 Vesting…”

1 older entry not shown

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

2 reverse splits in 5 years (1:30 on Feb 5, 2024, 1:25 on Sep 8, 2026) · 1:750 cumulative

The other times: of 247 securities that repeated a reverse split in 5 years, a year later the median was worth 0.10× the price on the day of the split; 189 lost more than half and 21 rose (243 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 782)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 13, 26DEF 14A ↗Shareholder meeting and votes new
  • Oct 9, 26S-1 ↗Securities offering
  • Oct 2, 26PRE 14A ↗Shareholder meeting and votes
  • Sep 25, 268-K ↗Current report · Other events
  • Sep 21, 268-K ↗Current report · Entered a material agreement
  • Sep 15, 268-K ↗Current report · Entered a material agreement
  • Sep 15, 26SCHEDULE 13G ↗Passive stake · RainForest Partners, LLC · 10.0%
  • Sep 3, 268-K ↗Current report · Change in shareholder rights · Bylaws or fiscal year change · Other events
  • Aug 14, 268-K ↗Current report · Shareholder vote results
  • Aug 14, 2610-Q ↗Quarterly report
  • Jul 2, 26DEF 14A ↗Shareholder meeting and votes
  • Jun 18, 26PRE 14A ↗Shareholder meeting and votes
  • Jun 12, 268-K ↗Current report · Bylaws or fiscal year change
  • May 22, 268-K ↗Current report · Listing notice (8-K 3.01)
  • May 15, 2610-Q ↗Quarterly report
  • May 13, 26424B3 ↗Securities offering
  • May 11, 26CORRESP ↗Correspondence with the SEC
  • May 6, 26UPLOAD ↗Correspondence with the SEC
  • Apr 30, 26S-1 ↗Securities offering
  • Apr 7, 268-K ↗Current report · Entered a material agreement
  • Mar 6, 2610-Q/A ↗Quarterly report · amendment
  • Mar 6, 2610-Q/A ↗Quarterly report · amendment
  • Mar 2, 2610-K ↗Annual report
  • Mar 2, 268-K ↗Current report · Past accounts declared unreliable and being restated
  • Jan 30, 26424B3 ↗Securities offering

782 filings on record, the oldest from May 12, 95.

Listing the 25 most recent filings of the 782 on record.

8-Ks, explained

Stress12Structure146Governance61
  • Sep 21, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Sep 15, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • May 22, 26StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Apr 7, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Mar 2, 26StressPast accounts declared unreliable and being restated+1 more in the same filing8-K 4.02 ↗
  • Nov 26, 25StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Aug 29, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jun 11, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • May 27, 25StructureSold unregistered shares+4 more in the same filing8-K 3.02 ↗
  • May 13, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • May 13, 25StructureSold unregistered shares+4 more in the same filing8-K 3.02 ↗
  • May 5, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗

11 older filings not shown · The record reaches back to Aug 24, 04.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Nov 27, 24StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Aug 22, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Feb 28, 23StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Nov 26, 21StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Apr 16, 21StressPast accounts declared unreliable and being restated8-K 4.02 ↗
  • Sep 21, 06StressA debt obligation was accelerated+2 more in the same filing8-K 2.04 ↗
  • Dec 8, 05StressRestructuring plan with committed costs+4 more in the same filing8-K 2.05 ↗

The full record holds 12 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Apr 11, 23Buy$25KMichael Martin BreenExecutive Chairman/Interim CEO↗
  • Apr 6, 23Buy$25KManu OhriCFO & Secretary↗
Stock compensation, tax and giftsshow the 4 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 11, 23Compensation$57KMichael Martin BreenExecutive Chairman/Interim CEO↗
  • Aug 11, 23Compensation$57KManu OhriCFO & Secretary↗
  • Aug 11, 23Other$57KManu OhriCFO & Secretary↗
  • Aug 11, 23Other$57KManu OhriCFO & Secretary↗

The full record holds 6 transactions and goes back to Jan 27, 23.

Its sector and its market

GT Biopharma, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From GT Biopharma, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow GT Biopharma, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
782 documents on file, from May 12, 1995 to Oct 13, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.